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Abstract
All living organisms contain a unique class of molecular chaperones called 60 kDa heat shock 
proteins (HSP60 – also known as GroEL in bacteria). While some organisms contain more than 
one HSP60 or GroEL isoform, at least one isoform has always proven to be essential. Because of 
this, we have been investigating targeting HSP60 and GroEL chaperonin systems as an antibiotic 
strategy. Our initial studies focused on applying this antibiotic strategy for treating African 
sleeping sickness (caused by Trypanosoma brucei parasites) and drug-resistant bacterial infections 
(in particular Methicillin-resistant Staphylococcus aureus – MRSA). Intriguingly, during our 
studies we found that three known antibiotics – suramin, closantel, and rafoxanide – were potent 
inhibitors of bacterial GroEL and human HSP60 chaperonin systems. These findings prompted us 
to explore what other approved drugs, natural products, and known bioactive molecules might also 
inhibit HSP60 and GroEL chaperonin systems. Initial high-throughput screening of 3,680 
approved drugs, natural products, and known bioactives identified 161 hit inhibitors of the 
Escherichia coli GroEL chaperonin system (4.3% hit rate). From a purchased subset of 60 hits, 29 
compounds (48%) re-confirmed as selective GroEL inhibitors in our assays, all of which were 
nearly equipotent against human HSP60. These findings illuminate the notion that targeting 
chaperonin systems might be a more common occurrence than we previously appreciated. Future 
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studies are needed to determine if the in vivo modes of action of these approved drugs, natural 
products, and known bioactive molecules are related to GroEL and HSP60 inhibition.
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Molecular chaperones are a class of proteins that cells have developed to help fold 
polypeptides to their native states, or target them for degradation.1–7 The 60 kDa heat shock 
proteins (HSP60 – also known as GroEL in bacteria) are a unique class of the molecular 
chaperone family that function by encapsulating unfolded polypeptides in the central cavity 
of an HSP60 ring, allowing them to fold while sequestered from the cellular milieu.8–14 
HSP60 chaperonins accomplish this in an ATP-dependent fashion with the assistance of co-
chaperones called HSP10 (GroES in bacteria), which are “lid” structures that cap off 
folding-active HSP60 rings (hence, we typically refer to them as HSP60/10 and GroEL/ES 
chaperonin systems). While some organisms contain more than one HSP60 or GroEL 
isoform, one has always proven to be essential, at least in the micro-organisms thus far 
evaluated.15–33 Because of this, we hypothesize that these chaperonin systems are viable 
antibiotic targets. Since HSP60/10 and GroEL/ES chaperonin systems are highly conserved 
across all organisms, we envision that this could be a broad-spectrum antibiotic strategy. 
While human cells also contain an HSP60/10 homolog, located in mitochondria, our 
accumulating evidence supports that even if compounds can inhibit HSP60/10 in vitro, many 
of these inhibitors are non-toxic to human cells and in vivo.34–37 No drugs have been 
developed to specifically inhibit HSP60/10 or GroEL/ES chaperonins, and thus we believe 
that targeting these molecular machines offers significant promise to address the problem of 
antibiotic-resistant infectious organisms.
As a first step in our research, we previously conducted a high-throughput screen of 
~700,000 small molecules and identified 235 inhibitors of the prototypical GroEL/ES 
chaperonin system from Escherichia coli.38 One lead hit, the bis-sulfonamido-2-
arylbenzimidazole compound A (Figure 1), was isostructural to another molecule identified 
in the PubChem database (compound B), which was reported to inhibit the growth of 
Leishmania parasites.39 As an extension, we developed a library of compound B analogs and 
Stevens et al. Page 2
Bioorg Med Chem Lett. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
screened them against Trypanosoma brucei, a related parasite that causes African sleeping 
sickness.35 Surprisingly, in that study we found that suramin (28), the first-line treatment for 
T. brucei infections in humans, was capable of inhibiting Escherichia coli GroEL/ES (which 
we typically use as a surrogate for compound evaluation) as well as human HSP60/10. To 
further support that this interaction was real, in the present study, we analyzed the suramin-
GroEL binding properties using Isothermal Titration Calorimetry (see the Supporting 
Information for a detailed protocol for this experiment). An isotherm for a representative 
suramin-GroEL binding analysis is presented in Figure 2, with the thermodynamic 
parameters, binding affinities, and binding stoichiometries averaged from triplicate analyses 
presented in Table 1. We found that suramin had a Kd of 21 μM for binding to E. coli 
GroEL, which corresponds reasonably well with the IC50 values for suramin inhibition in 
our assays that monitor GroEL/ES-mediated refolding of dMDH and dRho. While this 
analysis shows the suramin-GroEL interaction is indeed real, what remains to be seen is 
what contribution suramin’s binding to the three HSP60s in T. brucei make to its anti-
trypanosomal effects. Future studies will need to explore this, but are beyond the scope of 
the present study.
In three additional follow up studies to our high-throughput screen, we explored the 
antibacterial properties of a subset of 22 of our hit GroEL inhibitors, plus additional 
compound B analogs and a series of analogs based on a bisarylamide hit-to-lead scaffold.
34, 36, 37
 During these studies, we discovered that two known anthelmintics used in 
veterinary medicine, closantel and rafoxanide, were also potent GroEL/ES and HSP60/10 
inhibitors.37, 40 In addition, other groups have identified a handful of natural products, such 
as epolactaene and myrtucommulone, that were able to target the human HSP60/10 
chaperonin system.41–44 Taken together, these accumulating findings prompted us to 
consider the possibility that targeting chaperonin systems with small molecule inhibitors 
may be more common than we previously thought. To shed further light on this possibility, 
we designed the present study to identify what other approved drugs, natural products, or 
known bioactive molecules might also inhibit HSP60/10 and/or GroEL/ES chaperonin 
systems.
In this study, we screened against the Library of Pharmaceutically Active Compounds 
(LOPAC) and the MicroSource Spectrum libraries, which together contain 3,680 approved 
drugs, natural products, and known bioactive molecules. For the primary high-throughput 
screen, we developed a new protocol that combined our traditional GroEL/ES-dMDH 
refolding and chaperonin-mediated ATPase assays into one multiplexed assay. A schematic 
representation of this multiplexed assay is presented in Figure 3, with a detailed description 
of the protocol provided in the Supporting Information. Using this assay, we screened the 
3,680 compound library and identified 219 compounds that inhibited >50% of the reporter 
enzymatic reaction, and thus putatively the refolding of the MDH reporter enzyme by the 
GroEL/ES chaperonin system. We found that none of the hits reduced ATPase activity, 
which was perhaps not surprising since in our previous high-throughput screen of ~700,000 
compounds, only a handful of hits were able to inhibit ATP hydrolysis by GroEL.38 We next 
conducted a secondary high-throughput screen of the entire 3,680 compounds using our 
traditional GroEL/ES-dRho refolding assay, which employs rhodanese (Rho) as the reporter 
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enzyme to be refolded by the chaperonin system.34, 36, 37 A detailed description of the 
protocol for this assay is presented in the Supporting Information. Since MDH and Rho have 
orthogonal enzymatic reactions (i.e. MDH catalyzes the oxidation of NADH in the presence 
of mesoxilic acid, while Rho catalyzes the conversion of cyanide to thiocyanate – two very 
different enzymatic reactions), we have typically found that these two refolding assays are 
effective at removing false-positive compounds that inhibit the refolded reporter enzymes. 
Percent inhibition results for these two assays are presented in Table S2 in the Supporting 
Information. While suramin was within the 3,680 compound library, we found that it did not 
meet the 50% inhibition cutoff in both of these assays, likely because the compound 
concentrations in the screens were near its IC50 values for inhibiting GroEL/ES refolding 
functions (~10–15 μM). While this suggests that if we tested the libraries at higher 
concentrations, or relaxed our inhibition cutoffs, we may find even more hits, we refrained 
from doing so as we had already obtained a high hit rate of 4.3% for compounds exhibiting 
>50% in both of the screens.
Upon examination of the 161 hits, we found a wide range of molecular structures, from as 
small as the single aryl mesalamine (23) to large, macrocyclic natural products like 
thiostrepton (24) and ivermectin (31). While singleton hits were identified, several hits were 
found that fell into distinct scaffold clusters, including analogs of suramin (1, 22, 28), 
chalcones (35, 43, 44), ivermectin (31–33), agaric acid (7, 8, 11, 20, 25, 27, 39, 42), and 
porphyrins (5, 19, 36). To further verify that hits were not false-positives owing to potential 
abnormalities in the library parent stocks or compounds that inhibit both the native MDH 
and Rho reporter enzymes, we selected a set of 60 hits to purchase purified powders of for 
confirmatory screening in our wider panel of established chaperonin-mediated biochemical 
assays. The structures of these hits are presented in Figure S1 in the Supporting Information, 
which were selected to maintain structural diversity while still probing some of the scaffold 
clusters. These 60 purchased compounds were re-screened in dose-response format in both 
of our traditional GroEL/ES-dMDH and GroEL/ES-dRho refolding assays, counter-screened 
in assays that monitor for false-positive inhibition of the refolded native MDH or Rho 
enzymatic reactions, and evaluated for inhibition of GroEL-mediated ATPase activity. Please 
refer to the Supporting Information for detailed protocols of these assays, and Table 2 for a 
compilation of IC50 values obtained in these assays. Consistent with results from the 
primary high-throughput screen, none of the compounds showed appreciable inhibition of 
GroEL-mediated ATPase activity. However, from the GroEL/ES-mediated refolding assays 
and native MDH and Rho reporter counter-screens, we were able to classify the 60 hits into 
four distinct inhibitor categories in order of decreasing selectivity for the GroEL/ES 
chaperonin system (Table 2): 12 compounds (20%) had >10x selectivity in both of the 
refolding assays (blue classification); 17 compounds (28%) exhibited >10x selectivity in one 
of the refolding assays, but not the other (green classification); 19 compounds (32%) 
exhibited between 1–10x selectivity in both of the refolding assays (yellow classification); 
and 12 compounds (20%) generally did not re-confirm as GroEL/ES inhibitors (orange 
classification).
Upon further analysis of the biochemical results, for the highly selective blue series 
molecules, we see a strong correlation between IC50 values obtained from the GroEL/ES-
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dMDH and -dRho refolding assays (Figure 4A), with a Spearman correlation coefficient of 
0.746 (p = 0.0071). While the green and yellow series are less selective, each still have 
moderate correlations between their IC50 values obtained in the two refolding assays, with 
Spearman correlation coefficients of 0.556 (p = 0.0223) and 0.601 (p = 0.0064), respectively. 
Few of these molecules, however, inhibited in both the native MDH and Rho reporter 
counter-screens (Figure 4B), suggesting they are likely still on target for inhibiting the 
GroEL/ES chaperonin system.
As an extension on potential selectivity concerns, because human HSP60 shares high 
homology to bacterial E. coli GroEL (~48% sequence identity), we counter-screened 
compounds 1–60 in an analogous HSP60/10-dMDH refolding assay. As seen in Figure 4C, 
there is a high correlation for compounds inhibiting both E. coli GroEL/ES and human 
HSP60/10: Spearman correlation coefficients are 0.853 (p = 0.0008) for the blue series, 
0.595 (p = 0.0132) for the green series, and 0.626 (p = 0.0042) for the yellow series 
compounds. These high correlations were not surprising based on results we have reported 
for other inhibitors, where we have only found a few scaffolds that can selectively inhibit E. 
coli GroEL/ES.34–37 While this raises the possibility of potential HSP60-dependent 
cytotoxicity to human cells, our ongoing studies support the notion that even though 
compounds can inhibit human HSP60/10 in vitro, this does not necessarily translate to 
cytotoxicity in vivo and would not preclude an inhibitor series from further development as 
an antibiotic candidate. For example, suramin inhibits human HSP60/10 in vitro, yet has 
been safely used for over 100 years as a first-line therapeutic for treating African sleeping 
sickness. A lack of cytotoxicity in vivo despite inhibition of HSP60/10 in vitro could be 
explained by the fact that compounds would need to be cell permeable and penetrate the 
highly impermeable mitochondrial membrane to even interact with HSP60/10 in the 
mitochondrial matrix. For chaperonin inhibitors that do affect the viability of human cells, 
whether they are natural products, synthetically derived, or even approved drugs or not, it 
will be important for future studies to determine whether or not their cytotoxicities are 
HSP60-dependent. As a first-pass indicator of general cellular toxicity, we employ Alamar 
Blue-based cell viability assays with a small panel of human cell lines from different tissues.
To further inform on the possibility that some of these compounds may exhibit promiscuous 
and pan-assay interference effects, we searched the PubChem database to see how many 
assays each of these compounds has been screened in, and the number of assays in which 
they have been classified as active hits.39 We have compiled these results in Table S1 in the 
Supporting Information. While some hits have only been reported tested in a handful of 
assays, most have been tested in hundreds, or even thousands, of assays. To more easily 
assimilate the data, in Figure S2A and S2B, we binned the aggregate results of the 
percentage assays that each molecule was reported active hits in, compared to their total 
number of reported assays. For example, 38.3% of compounds 1–60, and 37.4% of all hit 
compounds, were reported to be active in 0–10% of the assays (i.e. least promiscuous) they 
were tested in, as reported in the PubChem Database. The nearly identical distribution of the 
two series may indicate the compounds purchased for confirmatory evaluation (1–60) are a 
suitable subset that is representative of the complete set of 161 GroEL/ES inhibitor hits 
identified from the initial screens. We further compared the PubChem % Actives results for 
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compounds 1–60 to their IC50 values from the GroEL/ES refolding assays to see if there was 
any evidence of more potent GroEL/ES inhibitors being inherently selective or promiscuous; 
however, we did not observe any correlation (Figure S2C). We exercise a word of caution in 
over-interpreting these results, though, as we have not further dissected the actual assays that 
each compound was tested in – for example, it would actually be beneficial if compounds 
were tested and reported active in a high proportion of infectious organism proliferation 
assays. With some compounds being tested in hundreds to thousands of assays, such a 
detailed analysis would be best suited for future studies of individual compounds. As an 
overview, we have compiled a brief listing of reported bioactivities for each of the 161 hits 
in Table S1 in the Supporting Information. While the bioactivities presented are far from 
exhaustive, they begin to paint a picture that targeting chaperonin systems could play a 
significant role in a number of indications, including inflammation, autoimmunity, cancer, 
and, in the context of the present study, antibiotic applications.
Through our own ongoing studies, we continue to accumulate evidence that targeting the 
GroEL/ES or HSP60/10 chaperonin systems of infectious organisms is a promising strategy 
for antibiotic development.34–37 We have identified chaperonin system inhibitors that are 
cytocidal to T. brucei parasites and Gram-positive bacteria, even towards S. aureus bacteria 
that reside in already established biofilms. As discussed above, despite having the ability to 
inhibit human HSP60/10 in vitro, many of our most potent GroEL/ES inhibitors exhibit low-
to-no cytotoxicity to human cells in culture. Intriguingly, the present study screening the 
LOPAC and MicroSource Spectrum libraries helps to further substantiate these findings as 
30% of the 161 GroEL/ES hit inhibitors are reported to have antimicrobial effects against a 
variety of pathogens, ranging from in vitro observations to practical use in household surface 
disinfectants and approved broad-spectrum antibiotics used clinically. Examples of these in 
the identified GroEL/ES and HSP60/10 inhibitor hits include suramin, ivermectin, retinoic 
acid, adapalene, cetylpyridinium chloride, abamectin, eprinomectin, benzethonium chloride, 
dichlorophen, curcumin, hexachlorophene, and hexadecyltrimethylammonium bromide. For 
some of these compounds, like suramin, definitive mechanisms of action have yet to be 
elucidated.45–51 Given the results presented herein, it is possible that some of these 
compounds may owe their antimicrobial effects to inhibition of the GroEL/ES and 
HSP60/10 chaperonin systems of the infecting pathogens.
In summary, in the present study, we screened a library of 3,680 known drugs, natural 
products, and bioactive compounds for their ability to inhibit the prototypical GroEL/ES 
chaperonin system from E. coli. The premise for this study was rooted in accumulating 
evidence, from us and others, indicating that it might not be uncommon for known drugs and 
natural products to target GroEL/ES and HSP60/10 chaperonin systems. From our two high-
throughput screens, we obtained an unusually high hit rate of 4.3%, from which we 
purchased purified powders of a subset of 60 hits for confirmatory evaluation in a panel of 
our chaperonin-mediated biochemical assays. Of this 60 hit subset, 29 compounds (49%) 
reconfirmed as GroEL/ES inhibitors with >10x selectivity in at least one of our chaperonin-
mediated refolding assays over our native MDH or Rho enzymatic reporter counter-screens, 
supporting that hits were on-target. With such a high hit and re-confirmation rate, this study 
suggests that targeting chaperonin systems might be a more common occurrence than we 
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previously appreciated. These findings further incentivize broader screening of additional 
known drugs, clinical candidates, and natural product libraries and extracts to identify more 
compounds that may be functioning against chaperonin systems. Intriguingly, we found that 
30% of the hits were reported to have antibiotic properties, thus further supporting the 
viability of a chaperonin-targeting antibiotic strategy; however, the other 70% have other 
reported bioactivities, including effects on inflammation, autoimmunity, and cancer, to name 
a few. While this may not be surprising as we found that most compounds were nearly 
equipotent inhibitors of both the human HSP60/10 and E. coli GroEL/ES chaperonin 
systems, a new question emerges: how much, if any, can the bioactivities of these known 
drugs and natural products be attributed to targeting GroEL/ES and HSP60/10 chaperonin 
systems?
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Figure 1. 
Structures of compounds previously found to inhibit E. coli GroEL/ES and/or human 
HSP60/10 chaperonin systems.
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Figure 2. 
Representative analysis of the binding of suramin (28) to E. coli GroEL measured by 
Isothermal Titration Calorimetry (ITC). The top panel shows a representative binding 
isotherm obtained by titrating suramin (2 mM) into a solution of GroEL (150 μM monomer 
concentration) in the ITC cell. The lower panel shows the integrated data (solid squares) fit 
to a single-site binding model (solid line). The molar ratio refers to the binding 
stoichiometry of suramin to monomeric GroEL. Average results for the various binding 
parameters (Kd, n, ΔH, ΔS, and ΔG) obtained from triplicate analyses are presented in Table 
1.
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Figure 3. Protocol for the primary multiplexed high-throughput screening assay.
For primary screening of the LOPAC and MicroSource Spectrum libraries, we employed a 
new assay where we combined our individual GroEL/ES-dMDH refolding and GroEL/ES-
dMDH ATPase assays into one multiplexed format. In this assay, a solution containing 
GroES and a binary complex of denatured malate dehydrogenase (dMDH) bound to GroEL 
was dispensed into the wells of a 384-well microplate. Compounds from the LOPAC and 
MicroSource Spectrum libraries (single concentrations) were then pin-transferred into the 
wells. The chaperonin-mediated refolding cycle was initiated by addition of ATP, the plates 
were incubated at 37°C for ~30 minutes (t1 – until ~90% of the dMDH would have been 
refolded in the absence of inhibitors), and EDTA was then added to quench the refolding 
cycle. The substrates for the refolded, native MDH (nMDH) were added (sodium mesoxalate 
and NADH) and the enzymatic reporter reaction was monitored over time by reading well 
absorbance at 340 nm (t2 – until the DMSO control wells had reached ~90% conversion of 
NADH to NAD+). In this coupled assay, the extent of chaperonin inhibition is proportional 
to the amount of enzymatic activity, and thus refolded MDH, present. In the same plate, we 
then added the malachite green phosphate reporter reagents to evaluate chaperonin-mediated 
hydrolysis of ATP.
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Figure 4. 
Correlation plots of IC50 values for compounds tested in the respective biochemical assays. 
Each data point represents results for individual compounds tested in the respective assays, 
with color coding of points corresponding to the selectivity classifications of compound 
results presented in Table 2. Compounds inhibited nearly equipotently in both the 
GroEL/ES-dMDH and GroEL/ES-dRho refolding assays (panel A, Spearman correlation 
coefficients presented in Table 2), with few that inhibited both the native MDH and Rho 
reporter counter-screens (panel B), supporting on-target effects against the chaperonin-
mediated refolding cycle. Compounds inhibited the human HSP60/10 and E. coli GroEL/ES 
chaperonin systems nearly equipotently, suggesting binding sites may be highly conserved 
between the two (panel C, Spearman correlation coefficients presented in Table 2). As 
indicated in panel A, For the purposes of categorizing inhibitor potencies in the various 
biochemical assays, we consider compounds with IC50 values plotted in the grey zones to be 
inactive (i.e. greater than the maximum concentrations tested), >30 μM to be weak 
inhibitors, 10–30 μM moderate inhibitors, 1–10 μM potent inhibitors, and <1 μM very potent 
and acting near stoichiometrically since the concentration of GroEL tetradecamer is 50 nM 
during the refolding cycle (i.e. 700 nM GroEL monomeric subunits).
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Table 1.
IC50 values for compounds tested in our GroEL/ES-mediated substrate enzyme refolding assays, the native 
enzymatic reporter counter screens (vide infra), and ITC analytical results for suramin (28) binding to E. coli 
GroEL. Binding parameter results are averaged from three replicate analyses. Binding is predominantly 
entropically driven, with a moderate enthalpic contribution to affinity. Particularly interesting is that suramin 
binds with a stoichiometry of ~9 molecules per GroEL tetradecamer and, since suramin does not inhibit 
GroEL ATPase activity, it is likely binding to unknown sites outside of the ATP pockets.
Suramin (28)
Assay IC50 (μM)
 GroEL/ES-dMDH Refolding 8.1
 GroEL/ES-dRho Refolding 16
 Native MDH reporter activity >63
 Native Rho reporter activity >100
Stoichiometry n
 Molecule : GroELmonomer 0.67 ± 0.05
 Molecule : GroELoligomer 9.4 ± 0.6
Thermodynamic parameters
 Log(K d /μM) 1.31 ± 0.30
 K d (μM) 21
 ΔH (kcal/mol) −2.07 ± 0.36
 ΔS (kcal/mol·K) 0.014 ± 0.002
 TΔS (kcal/mol) 4.15 ± 0.72
 ΔG (kcal/mol) −6.22 ± 0.41
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Table 2.
Compilation of IC50 values from the respective biochemical assays. Compounds are ordered from most 
selective in the refolding assays at the top, to lower selectivity going down the table. Compounds colored blue 
exhibit >10x selectivity in both of the GroEL/ES-mediated refolding assays compared to the native MDH and 
Rho enzymatic reporter counter screens; compounds colored green exhibit >10x selectivity in one of the 
refolding assays, but not the other; compounds colored yellow exhibit between 1–10x selectivity in both of the 
refolding assays; and compounds colored orange generally did not re-confirm as GroEL/ES inhibitors.
Biochemical Assay IC50 (0μM)
Compound Native Rho Native MDH GroEL/ES-mediated refolding of HSP60/10-dMDH GroEL
# Name Reporter Reporter dRho dMDH Refolding ATPase
1 Evans blue 8.7 19 0.087 0.039 0.17 161
2 (±)-Gossypol-acetic acid 11 48 0.43 0.66 1.2 >250
3 Adapalene >100 >63 5.1 2.1 2.3 >250
4 Curcumin 56 >63 2.9 3.1 8.3 >250
5 Protoporphyrin IX >100 >63 3.0 4.4 4.9 >250
6 Ethacrynic acid >100 >63 4.7 5.2 8.5 >250
7 Agaric acid >100 >63 8.9 3.5 4.0 >250
8 Cetylpyridinium chloride >100 >63 8.9 4.2 6.0 152
9 Epigallocatechin gallate (EGCG) 7.3 16 0.58 0.36 2.3 >250
10 Hexachlorophene 51 18 4.7 1.4 1.3 153
11 Hexadecyltrimethylammonium bromide >100 >63 12 6.5 7.4 210
12 Hematein 12 46 1.2 1.8 3.6 >250
Spearman Correlation Coefficient & 
p value
0.746 (p = 0.0071)
0.853 (p = 0.0008)
13 Aurintricarboxylic acid >100 3.0 0.57 0.90 3.2 >250
14 Erythrosin B 9.2 33 1.2 0.50 2.9 222
15 β-laphachone 0.12 >63 0.59 1.3 2.1 >250
16 Closantel >100 6.2 2.0 2.2 2.8 >250
17 Tannic acid 39 4.6 1.0 0.87 3.8 137
18 Gossypetin 0.33 >63 0.39 2.1 7.5 >250
19 Chlorophyllin sodium copper salt 11 >63 1.2 2.3 4.4 >250
20 L-Ascorbyl palmitate 53 >63 8.5 3.5 3.1 177
21 Plumbagin 0.060 >63 0.29 3.8 6.3 >250
22 Pontamine sky blue 8.5 >63 2.0 3.9 6.8 >250
23 Mesalamine 0.28 >63 0.49 6.0 12 >250
24 Thiostrepton >100 >63 16 6.8 13 >250
25 Retinoic acid 91 >63 21 6.7 5.3 >250
26 Morin hydrate 57 47 5.2 8.5 11 >250
27 Arachidonic acid >100 >63 18 7.3 4.5 >250
28 Suramin >100 >63 16 8.1 7.2 >250
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Biochemical Assay IC50 (0μM)
Compound Native Rho Native MDH GroEL/ES-mediated refolding of HSP60/10-dMDH GroEL
# Name Reporter Reporter dRho dMDH Refolding ATPase
29 Bithionol >100 24 13 4.3 2.8 >250
Spearman Correlation Coefficient & 
p value
0.556 (p = 0.0223)
0.595 (p = 0.0132)
30 Menadione 1.0 >63 2.5 9.0 15 >250
31 Ivermectin >100 >63 23 9.5 16 >250
32 Abamectin (Avermectin b1a) >100 >63 32 9.8 15 >250
33 Eprinomectin >100 >63 38 11 17 >250
34 Crystal violet 16 >63 15 11 5.8 >250
35 4’-Methoxychalcone >100 >63 30 13 16 >250
36 Cyanocobalamin (vtamin B12) 0.66 >63 0.12 16 12 >250
37 Purpurin 2.3 >63 4.0 15 23 >250
38 Lithocholic acid >100 >63 59 16 10 >250
39 Benzethonium chloride >100 >63 26 24 23 >250
40 Benzbromarone >100 >63 49 18 9.1 >250
41 Cholecalciferol (vtamin D3) >100 >63 31 22 11 >250
42 4-Nonylphenol 72 47 29 12 9.5 >250
43 4-Hydroxychalcone >100 >63 40 21 22 >250
44 4’-Hydroxychalcone >100 >63 56 21 20 >250
45 Dichlorophen >100 >63 66 24 17 >250
46 Calciferol (Vtamin D2) 94 >63 41 28 45 >250
47 Phenoxybenzamine HCl >100 >63 129 40 78 >250
48 Paclitaxel >100 >63 114 56 >100 >250
Spearman Correlation Coefficient & 
p value
0.601 (p = 0.0064)
0.626 (p = 0.0042)
49 Primiquine 2.9 >63 6.2 75 >100 103
50 Riboflavin-5-phosphate sodium salt 0.38 >63 0.77 85 80 >250
51 Ethidium bromide 0.83 >63 2.4 >100 >100 >250
52 Methylene blue trihydrate 6.1 >63 3.3 >100 >100 >250
53 Riboflavin 8.8 >63 18 >100 >100 >250
54 Harmalol 9.7 >63 16 >100 >100 >250
55 (−)-Erythromycin >100 >63 178 >100 >100 >250
56 Candesartan >100 >63 >250 >100 >100 >250
57 Albuterol >100 >63 >250 >100 >100 >250
58 Nalbuphine >100 >63 >250 >100 >100 >250
59 SB 204070 >100 >63 >250 >100 >100 >250
60 Fluvastatin sodium >100 >63 >250 >100 >100 >250
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